7 papers in the library · 131 citations · publishing 2022-2026
The British Journal of Psychiatry August 10, 2026 Yi Zhang, Yongbo Zheng, Meng Jin et al.
Psychedelics hold promise for psychiatry, yet clinical translation remains premature. Addressing the challenges of psychedelics in psychiatry requires advances in mechanistic study, clinical implementation, regulatory governance and public discourse in parallel.
Neurotherapeutics 2026 Ziran Huang, Xiaoyan Wei, Yihui Wang et al.
Recent clinical breakthroughs hold great promise for the application of psilocybin in the treatments of psychological disorders, such as depression, addiction, and obsessive-compulsive disorder. Psilocybin is a psychedelic whose metabolite, psilocin, is a 5-HT2A receptor agonist. Nevertheless, the underlying mechanisms for the effects of psilocybin on the brain are not fully illustrated, and...
Translational neurodegeneration July 25, 2025 Chonglei Fu, Xuehui Li, Xiaoxing Liu et al. 2 citations
Alzheimer's disease (AD) is a major neurodegenerative disorder that causes severe cognitive decline and poses a significant burden on global health systems. Despite extensive research, effective treatments to stop neurodegeneration or promote neuronal regeneration in AD remain elusive. Psychoactive substances as modulators of neurophysiological functions, have received increased attention in...
Psychiatry Research May 1, 2024 Yuan Yao, Dan Guo, Tang-Sheng Lu et al. 126 citations
We aim to systematically review and meta-analyze the effectiveness and safety of psychedelics [psilocybin, ayahuasca (active component DMT), LSD and MDMA] in treating symptoms of various mental disorders. Web of Science, Embase, EBSCO, and PubMed were searched up to February 2024 and 126 articles were finally included. Results showed that psilocybin has the largest number of articles on...
bioRxiv (Cold Spring Harbor Laboratory) January 7, 2024 Ziran Huang, Xiaoyan Wei, Xiaobin Wang et al. 3 citations preprint
Abstract Recent clinical breakthroughs hold great promise for the application of psilocybin in the treatments of psychological disorders, such as depression, addiction, and obsessive-compulsive disorder. Psilocybin is a psychedelic whose metabolite, psilocin, is a 5-HT 2A receptor agonist. Nevertheless, the underlying mechanisms for the effects of psilocybin on the brain are not fully...
Journal of Affective Disorders February 1, 2022 Jianyu Que, Le Shi, Wei Yan et al.
Background Trauma experience increases the risk of suicidal ideation, but little is known about potentially psychological mechanisms underlying this relationship. This study aims to examine the relationship between coronavirus disease 2019 (COVID-19)-related traumatic event (CTE) exposure and suicidal ideation among hospital workers, and identify mediating roles of sleep disturbances in this...
Frontiers in Psychology 2022 Yundong Ma, Xia Feng, Di Wang et al.
Dreams can be affected by recent life events and long-term life experiences. Previous evidence has shown that childhood adverse experiences are associated with sleep quality and dream experiences. The aim of this study was to explore the relationship between childhood adverse experiences and dream content in adults. A total of 163 participants without current or past physical or mental...